Much of the work involving GHS administration in humans has examined serum GH or IGF-1 secretion after short treatment courses, finding that GH and IGF-1 levels increase in both adults and children after GHS administration(29–38). No adverse effects of L-163,191 were observed during this 14 day study, and the drug entered clinical development as MK-0677, also known as ibutamoren mesylate. This original GHRP mimics growth hormone releasing hormone (GHRH), but was found to only weakly stimulate GH secretion in vitro(23). These concerns arose from large European studies that followed children on long-term recombinant GH therapy and observed increased mortality in the cohort(18). Due to its anabolic effects, the use of recombinant GH has been studied in GH deficient adults examining a variety of endpoints, including bone mineral density, exercise tolerance and performance, muscle strength, skin effects, immune function, and quality of life, among others(3). Growth hormone (GH), which is produced by somatotroph cells of the anterior pituitary, exhibits pulsatile secretion that promotes linear growth in children by acting on the epiphyseal plates of the long bones(1). Treatment with ibutamoren also resulted in an approximate 50% increase in slow-wave sleep in young subjects.
Although no studies longer than 2 months have been performed in obese individuals, 2 months of daily 25 mg ibutamoren treatment in 12 obese individuals was well tolerated compared to 12 obese controls(56). Another double-blind, multicenter study of 563 patients with mild to moderate Alzheimer’s disease were randomized to receive ibutamoren or placebo daily for 12 months, with serious drug-related clinical AE rates that were comparable between groups. In this study, serious AEs were similarly distributed between the ibutamoren and placebo groups, apart from more thromboses reported in the ibutamoren group, though these were not thought to be drug related(50). More generally, more AEs were reported in patients on ibutamoren than in those on placebo (48 (77%) vs. 33 (55%), respectively) in this study. Four patients in the ibutamoren group (6.5%) and one in placebo group (1.7%) developed CHF during the study, though the higher CHF rate in the ibutamoren group may have been due in part to higher baseline blood pressures in that group(51).
Increased growth hormone and IGF-1 promote the development of new bone tissue and maintain bone mass, lowering your risk of fractures while promoting overall bone health. It binds to one of the growth hormone secretagogue receptors (GHSR) in the brain, helping increase growth hormone (GH) levels. Elevated growth hormone levels have been shown to stimulate the secretion of luteinizing hormone (LH), which in turn stimulates testosterone production in the testes. Critically, some growth hormone secretagogues, including MK-677, can cause a mild to moderate increase in prolactin levels. In a follow-up study, Veldhuis and colleagues assessed the effects of age, IGF-1 levels and AVF on GHRH and GHRP treatment response in 25 healthy men (43). Although body weight, body fat, and testosterone levels were unchanged, these findings demonstrate the potential for sermorelin as adjunctive or alternative therapy in hypogonadal men, and further highlight the need for additional long-term studies. These results highlight that, compared to the short-term treatment in the Vittone study, longer term treatment with sermorelin results in increases in GH and IGF-1 in addition to changes in body composition seen with increased lean body mass.
Neither the serum cortisol nor the PRL response was significantly greater after 7 days of MK-677 dosing compared with 7 days of placebo. In fact, those who took MK-677 helped reverse diet-induced nitrogen-wasting without any side effects. IGF-1 is a hormone with a similar function and molecular structure to insulin. Ibutamoren does not directly affect testosterone production, as it does not interact with the hypothalamic-pituitary-gonadal axis responsible for testosterone regulation.
The increases in GH and PRL after the initial dose were significantly greater than the increase seen after multiple doses. BMR refers to the rate at which the body uses energy while at rest. This goes to show that MK-677 can help with catabolic conditions such as muscle wasting, especially in people with acute or chronic disease states.

Gender: Female

Social links